284 related articles for article (PubMed ID: 30808420)
21. Pathological findings in enucleated eyes after intravitreal melphalan injection.
Ghassemi F; Amoli FA
Int Ophthalmol; 2014 Jun; 34(3):533-40. PubMed ID: 24043335
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal Lower-Dose (20 µg) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds.
Tuncer S; Balcı Ö; Tanyıldız B; Kebudi R; Shields CL
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):942-8. PubMed ID: 26469234
[TBL] [Abstract][Full Text] [Related]
23. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.
Shields CL; Alset AE; Say EA; Caywood E; Jabbour P; Shields JA
J Pediatr Ophthalmol Strabismus; 2016 Sep; 53(5):275-84. PubMed ID: 27486728
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of intravitreal injections of melphalan in the treatment of retinoblastoma vitreous seeding.
Cieślik K; Rogowska A; Danowska M; Hautz W
Adv Clin Exp Med; 2024 Feb; 33(2):119-125. PubMed ID: 37260052
[TBL] [Abstract][Full Text] [Related]
25. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review.
Smith SJ; Smith BD; Mohney BG
Br J Ophthalmol; 2014 Mar; 98(3):292-7. PubMed ID: 24187047
[TBL] [Abstract][Full Text] [Related]
26. Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma.
Hsieh T; Liao A; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
PLoS One; 2020; 15(7):e0235016. PubMed ID: 32609726
[TBL] [Abstract][Full Text] [Related]
27. Intra-Arterial Chemotherapy for Retinoblastoma: A Single-Center Experience.
Akyüz C; Kıratlı H; Şen H; Aydın B; Tarlan B; Varan A
Ophthalmologica; 2015; 234(4):227-32. PubMed ID: 26368674
[TBL] [Abstract][Full Text] [Related]
28. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg.
Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160
[TBL] [Abstract][Full Text] [Related]
29. Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track.
Munier FL; Soliman S; Moulin AP; Gaillard MC; Balmer A; Beck-Popovic M
Br J Ophthalmol; 2012 Aug; 96(8):1084-7. PubMed ID: 22368262
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.
Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era.
Berry JL; Shah S; Bechtold M; Zolfaghari E; Jubran R; Kim JW
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28646513
[TBL] [Abstract][Full Text] [Related]
32. Management of cataracts secondary to intravitreal chemotherapy injections for retinoblastoma seeding.
Koç İ; Taylan Şekeroğlu H; Kıratlı H; Lotfisadigh S
Eur J Ophthalmol; 2022 May; 32(3):1766-1771. PubMed ID: 34082595
[TBL] [Abstract][Full Text] [Related]
33. Alternated intra-arterial and intravitreal chemotherapy for advanced intraocular retinoblastoma: preliminary successful results without systemic chemotherapy.
De Francesco S; Galluzzi P; Bracco S; Menicacci F; Motolese E; Hadjistilianou T
Int Ophthalmol; 2015 Dec; 35(6):887-95. PubMed ID: 26416040
[TBL] [Abstract][Full Text] [Related]
34. INTRAVITREAL MELPHALAN AS SALVAGE THERAPY FOR REFRACTORY RETINAL AND SUBRETINAL RETINOBLASTOMA.
Francis JH; Marr BP; Brodie SE; Gobin P; Dunkel IJ; Abramson DH
Retin Cases Brief Rep; 2016; 10(4):357-60. PubMed ID: 26630243
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.
Bogan CM; Kaczmarek JV; Pierce JM; Chen SC; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Nadelmann JB; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Br J Ophthalmol; 2022 Feb; 106(2):288-296. PubMed ID: 33972235
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal injection of melphalan in the treatment of retinoblastoma with vitreous cavity seeding.
Sun YB; Hui P; Punyara K; Bi MC; Li SH; Teng SY; Song E
Chin Med J (Engl); 2013; 126(8):1587. PubMed ID: 23595400
[No Abstract] [Full Text] [Related]
37. Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds.
Smith SJ; Pulido JS; Salomão DR; Smith BD; Mohney B
Br J Ophthalmol; 2012 Aug; 96(8):1073-7. PubMed ID: 22368261
[TBL] [Abstract][Full Text] [Related]
38. Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding.
Karl MD; Francis JH; Iyer S; Marr B; Abramson DH
J Pediatr Ophthalmol Strabismus; 2017 May; 54(3):185-190. PubMed ID: 28092395
[TBL] [Abstract][Full Text] [Related]
39. Anterior Ocular Toxicity of Intravitreous Melphalan for Retinoblastoma.
Francis JH; Marr BP; Brodie SE; Abramson DH
JAMA Ophthalmol; 2015 Dec; 133(12):1459-63. PubMed ID: 26378741
[TBL] [Abstract][Full Text] [Related]
40. Tethered vitreous seeds following intravitreal melphalan for retinoblastoma.
Francis JH; Marr BP; Brodie SE; Gobin YP; Abramson DH
JAMA Ophthalmol; 2014 Aug; 132(8):1024-5. PubMed ID: 25124953
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
